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mean age for the entire obese sub-sample was 54.8 (o15.5), compared to 45,8 (   o18,4) 
for the non-obese participants. 40.4% of the obese participants suffered from at least 
one comorbid disease such as hypertension, diabetes, hyperlipidaemia, compared to a 
much lower 21.1% for the remaining sample. The unadjusted SF-12 scores for obese 
and non-obese participants were: PCS 44.9 ( o12.0) and 50.5 (  o9.8) (Mann-Whitney, 
P  0.001) and MCS 45.8 (o10.1) KAI 49.6 (o 8.9) (Mann-Whitney, P  0.001). After 
adjusting for confounding variables, the respective scores were PCS 48.2 and 49.8   
(P  0.05, R2  37.9%), and MCS 47.1 and 49.3 (      P  0.01, R2  9.7%) respectively. 
CONCLUSIONS: Obesity signiﬁcantly affects physical and mental health. Recogniz-
ing the serious impact on health and HRQoL, and on the raising health care cost as 
well, formulating effective strategies to prevent obesity should become major public 
health priorities.
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OBJECTIVES: Obesity is a major risk factor for a number of chronic diseases, includ-
ing diabetes, cardiovascular diseases and cancer. Obesity and its comorbidities signiﬁ-
cantly depress patients quality of life. The aim of this study was to estimate the impact 
of obesity on quality of life in Polish population. METHODS: The 20-item WRSM 
(Weight-Related Symptom Measure) and EQ-5D (EuroQol) questionnaires as well 
VAS (visual analogue scale) were used to asses Qol in obese patients (BMI  30 kg/m2), 
treated in National Food and Nutrition Institute in Warsaw. We used EQ-5D Polish 
TTO-value set to estimate health uitlity. EQ-5D utility and VAS were compared to 
previously published Polish population norms (age speciﬁc for EQ-5D or age and sex 
speciﬁc for VAS). Data are presented as mean (SD). RESULTS: Data on 68 obese 
patients are available with 18 (26.5%) being severely obese (BMI  40). The mean 
age of observed population was 52.6 (12.6) years and mean BMI was calculated at 
37.2 (6.6) kg/m2. The mean state of health recorded on the visual analogue scale was 
72.6 (15.3). The mean utility value (EQ-index) was estimated at 0.868 (0.154). The 
mean WRSM value was estimated at 16.9 (16.6). The mean utility value was compa-
rable to age speciﬁc data (based on population with BMI  26.2) - 0.899; p  0.282, 
however mean VAS was signiﬁcantly (p  0.003) lower to this estimated based on age 
and sex speciﬁc norms (78.5 in a given population). There were weak correlations 
between BMI and either EQ-index (R2  0.11), VAS (R2  0.14) or WRSM (R2  0.15). 
Population of patients with severe obesity (BMI  40) had signiﬁcantly lower EQ-index 
and VAS and signiﬁcantly higher WRSM compared to the rest of obese population 
(p  0.044; 0.046 and 0.016 respectively). CONCLUSIONS: Obesity has signiﬁcant 
negative impact on patients quality of life. There is no straightforward correlation 
between BMI and QoL indices.
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OBJECTIVES: This part of DEFI study aimed at assessing Qol in a FM population 
whose diagnosis was suspected or clinically conﬁrmed. METHODS: In a French cross-
sectional study, 6000 subjects were screened by phone using the French validated 
London Fibromyalgia Epidemiological study Screening Questionnaire (LFES-SQ) 
which was positive for 232 of them (LFES-SQ). On this population 145 accepted to 
ﬁll in SF36 and were proposed a rheumatologist consultation : 49 refused but ﬁlled 
in questionnaires, 20/96 who accepted the consultation and questionnaires (CS) were 
diagnosed as FM (FM) on the ACR criteria. RESULTS: Normalized SF36 subscales 
mean values of LFES-SQ subjects are as follow: Physical Functioning (PF) 42.3 o 
10.4, Role Physical (RP) 36,8 o 9.4, Bodily Pain (BP) 42,5 o 7.1, General Health (GH) 
39,9 o 9.6, Vitality (VT) 41.3 o 6.6, Social Functioning (SF) 43.5 o 9,4, Role Emo-
tional (RE) 43,7 o 9,4 , Mental Health (MH) 36,8 o 7.4. Physical component score 
(PCS) was 42.4 o 8.4 while mental component score (MCS) was 40.0 o 9.5. No sig-
niﬁcant differences were observed between CS and CS- subjects. In contrast, com-
parisons between the FM and FM- subjects showed in most cases signiﬁcant 
differences : PF 37.7 o 8.1 vs 44.6 o 9.4 (p  0.003), RP 33.6 o 5.4 vs 36.9 o 10.0 
(p  0.053), BP 39.6 o 6.0 vs 43.5 o 6.1 (p  0.011), GH 33.2 o 8.2 vs 42.3 o 9.0 
(p  0.0001), VT 39.2 o 4.2 vs 44.7 o 6.3 (p  0.0001), SF 39.0 o 8.3 vs 45.8 o 
9.3 (p  0.004), RE 33.2 o 11.3 vs 44.9 o 14.1 (p  0.027), MH 33.5 o 5.2 vs 37.6 
o 7.2 (p  0.019), PCS 38.2 o 7.0 vs 43.6 o 7.8, (p  0.006), MCS 35.3 o 7.5 vs 41.6 
o 9.4 (p  0.008). CONCLUSIONS: This study demonstrated the alterations of SF36 
in positive screened and ACR criteria conﬁrmed FM subjects.
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OBJECTIVES: To assess potential individual factors inﬂuencing quality of life and 
pain scores of patients suffering from histologically conﬁrmed endometriosis. Study 
using a questionnaire among patients of reproductive age undergoing laparoscopy       
with a presumed diagnosis of endometriosis. METHODS: Details of fertility, previous 
treatments and quality of life, sexual activity, as well as linear pain scores for several 
symptoms, were recorded. Details of intraoperative ﬁndings were also collected and 
only those data were used where endometriosis was intraoperatively and histologically 
proven. A questionnaire before surgery gathered information from women on the          
following groups of variables: age, marital status, education, reproductive and medical 
history including previous pregnancies and parity, knowledge of accompanying pelvic 
disorders, regular sport activity, as well as general quality of life estimates including 
self-image. Pelvic pain was scored using a visual analogue scale. RESULTS: Eighty-one 
patients complaining about persistent pelvic pain were later intraoperatively and his-
tologically proven to have endometriosis. Thirty-one of them (38.2%) reported regular 
sport as part of their daily life schedule while 50 of them (61,8%) performed no 
physical activity at all. Fourteen patients among regular exercisers and 33 patients 
among those without physical activity reported the effectiveness of painkillers for 
pelvic pain, corresponding to 45.1% and 66% of these subgroups, respectively (dif-
ference statistically signiﬁcant, p  0.05). CONCLUSIONS: Based on our results, we 
can conclude, that taking painkillers might be less effective among endometriosis 
patients performing regular daily sport activities, and, thus it might impose them to 
an unnecessary burden of possible side effects.
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OBJECTIVES: To estimate effectiveness of enzyme replacement therapy (ERT) in the 
treatment of symptomatic Gaucher’s disease in the Ural’s cohort in Russia. METHODS: 
Information sources were the databases of regional registries in 3 big towns of Ural 
administration District of Russian Federation: Ekaterinburg, Perm, Chelyabinsk, 
updated January 2009. Most of the parameters were derived from the published lit-
erature. Doses of Cerezymeare varies from 1200 un. till 2000 un. ERT was assumed 
to restore patients to full health in the base case. Regional cohort include 21 patients, 
middle age 23 years old. Quality of life was tested by Short Form 36 (SF-36). 
RESULTS: Seventy percent of the patients were diagnosed in childhood and have 1 
type Gaucher Disease. The clinic characteristics were typical. Bone abnormalities were 
the most serious. Data on this topic were obtained from the primary medical sources. 
The mean cost of the disease calculated about a120,000. The cost per patient varied 
considerably by dose. Nonetheless , quality of life indicate that patients treated with 
ERT continue to have reduced health-related quality of life 0.5 compared with the 
general population 0.75. And as much more younger seriously sick patients started 
ERT-quality of life index could be higher. The social efﬁcacy of ERT equivalent extra 
number of life years, in this cohort it’s about 13.7 years.Economic evaluations were 
found, all of which calculated a very high cost per quality-adjusted life-year (QALY). 
Incremental cost per QALY incremental cost-effectiveness ratio (ICER) in the base 
case a210,000. CONCLUSIONS: Although ERT for treating the ‘average’ Gaucher’s 
disease patient supported by the national program for orphan diseases, despite of it 
great expense. However, although doing so will be of clinical interest, it is questionable 
whether, within the current pricing environment, such research would have any sub-
stantive impact on policy decisions.
SYSTEMIC DISORDERS/CONDITIONS – Health Care Use & Policy Studies
PSY55
IMPACT OF THE NEW RECOMMENDATIONS IN THE USE OF 
PROTHROMBIN COMPLEX CONCENTRATES AND VITAMIN K 
ANTAGONISTS IN FRANCE: ILLUSTRATION OF THE GUIDELINES 
RESPECT IN HOSPITAL AND ITS ECONOMIC CONSEQUENCES
Bernard M, Mimoun G, Arnaud P, Peytavin G
Bichat-Claude Bernard hospital, Paris, Ile de france, France
OBJECTIVES: New recommendations were elaborated in April 2008 in France 
regarding overdoses, situations of hemorrhagic risk and bleeding accidents occurring 
in patients treated with vitamin-K antagonists (VKA). Considering the necessity for 
hospitals to guarantee the good therapeutic use of drugs to obtain reimbursement by 
public health insurance, and with the signiﬁcant increase of prescriptions in 2008, a 
systematic follow-up of correspondence between prothrombin complex concentrates 
use (PCC, Kaskadil®) and current guidelines was analyzed. METHODS: A prospec-
tive study of patients treated with PCC in 2008 was conducted. Data collected 
included demographic, therapeutic (indication, dosage), biological (INR, PT), clinical 
(bleeding, surgery . . .) and pharmacoeconomic parameters. Results are expressed as 
median and interquartile range (IQR 25–75). RESULTS: Ninety-one patients (41 men, 
median age: 76 years) received PCC, namely 78.4% compared to 2007, for a total 
cost of a81 K (73%). Analysis of prescriptions reveals that indications corresponded 
to the marketing authorisation (MA): 36% of bleeding under VKA, 30% of urgent 
surgery or invasive procedure and 29% of overdose (INR  5). Fluindione was the 
mainly prescribed VKA (77%). Median values of INR were 4 (2.9–6.9) and PT 33.5% 
(24–54%). Median doses of PCC were in accordance with MA and recommendations: 
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18.6 UI/KG (14.2–19.6) for patients undergoing urgent surgery, 22.3 UI/KG (19.2–24, 
n: 41) for patients with overdose. In 66%, a risk factor of overdose was identiﬁed: 
age 75 years (63%), comorbidity (15% like diabetes). The median cost of PCC 
treatment was a888/patient (a592–a888) representing 9.3% of the total hospitalisa-
tion cost paid by national health insurance for those 91 patients. CONCLUSIONS: 
PCC was used according to the recommendations and in respect of the health care 
regulations for reimbursement. The high increase of prescription observed in 2008, 
mainly in the emergency department (48%), can be explained by a change of medical 
practices and prescribing behaviour since the new recommendations.
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OBJECTIVES: According to WHO data approximately 1.6 billion adults are over-
weight with at least 400 million being obese (BMI  30). In Western Europe up to 
4% of total expenditures on health care are spent on managing obesity and obesity 
dependent chronic diseases including diabetes, cardiovascular diseases and cancer. The 
aim of this systematic review was to ﬁnd studies on direct cost estimates of obesity 
and its comorbidities in Poland. METHODS: Search and selection of data was based 
on a protocol developed before proceeding with the search and compilation of data. 
Two researchers independently assessed publications according to pre-deﬁned inclu-
sion criteria and with regard to study methodology. The review covered following 
databases: MEDLINE, EMBASE and PBL (Polish Medical Bibliography). Last update 
of the search results have been made on May 10, 2009. RESULTS: In the result of 
the systematic review only 2 studies were found: Szponar et al. 2006 and Krzyza-
nowska et al. 2008. In those studies direct costs of treating obesity and associated 
diseases have been estimated at between 20 to 30% of the total health care expendi-
tures in Poland. Based on OECD data it gives the amount of 8.15 to 12.2 billion USD 
according to PPP in 2008. CONCLUSIONS: Economic burden of obesity and its 
comorbidities in Poland is undoubtedly signiﬁcant. In 4 European countries with 
obesity prevalence similar to Poland (Portugal, Norway, Belgium and Sweden), the 
cost of treating obesity and associated diseases has been estimated on average at 
0.32% GDP. If the cost of obesity and its comorbidities in Poland amounted also to 
0.32% of GDP, the total burden of disease could have been estimated at 1.95 billion 
USD. We conclude that speciﬁc Polish data from the two above mentioned studies can 
be signiﬁcantly overestimated and there is an urgent need for further research in order 
to estimate the true value of these costs.
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OBJECTIVES: Although health spending is well below the OECD average when con-
sidered as a share of GDP, Slovakias pharmaceutical expenditures accounts 32% of 
total health care budget. The accessibility and availability of innovative drugs is good. 
Mandatory HTA (pharmacoeconomy) is incorporated in all relevant legislation, MoH 
set the ofﬁcial threshold by l1  a18,000/QALY and l2  a26,500/QALY. METHODS: 
We have analysed the legislation and ofﬁcial reimbursement decisions and commentar-
ies, published by the MoH in 2009. We analysed the applicants documentation 
including pharmacoeconomic analysis, as a mandatory part of the application. 
RESULTS: The main drug reimbursement body—Categorisation committee of the 
MoH and pharmacoeconomic advisory committee evaluated the applicants dossier for 
the biologic drug ustekinumb (Stelara®, Jannssen Cilag Slovakia) for the treatment of 
psoriasis. The pharmacoeconomic part of the application fulﬁled all legislative aspects. 
The CEA shows that ustekinumab is more cost effective in cost of theraphy responder 
analysis vs. other biologics in the Slovak market for psoriasis treatment by 2%—60%. 
The price sensitivity analysis of comparators was done. The reassessment of CEA after 
massive price cut of comparators (up to 32%, due to international price referencing) 
has showed the positive results for ustekinumab and robustness of previous price 
sensitivity analysis. CONCLUSIONS: The focus of the MoH drug policy is on more 
rational spendings , especially on reference pricing and HTA. There are ﬁrst results 
of these new procedures, where the real impact of the HTA in the decision processes 
is demonstrated. Ustekinumb a new agent in therapy of psoriasis fulﬁlled the necessary 
legislative conditions including pharamacoeconomic aspects to be listed in the positive 
reimbursement list.
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OBJECTIVES: To describe the prescription pattern of rimonabant in relation to the 
approved indications and the stated limitations of reimbursement. Secondly to 
compare the efﬁciency and adverse effects in rimonabant treated patients with the 
impact of conventional care in matched controls without rimonabant treatment during 
a follow up period of up to 12 months. METHODS: The survey was based on retro-
spective collection of data through a speciﬁed extraction and data management 
method, Pygargus Customized eXtraction Program (CXP) developed to extract patient 
data from an Electronic Health Record (EHR) system (Profdoc Journal III). Centers 
were selected with a wide socio-economic and geographical spread. RESULTS: Body 
mass index (BMI) was available in 922 patients out of 1477 (62%). Of those patients, 
93% were prescribed rimonabant according to the indication and 79% within the 
reimbursement criteria. In reality, 97% of the total cohort obtained reimbursement. 
Patients prescribed rimonabant for at least 6 months showed a mean weight reduction 
of 6.0 kg after 12 months compared to 0.4 kg in controls. The mean decrease in 
HbA1c was 0.3% in patients with type-2 diabetes versus 0.0% in controls. More than 
half of patients and controls (54.4 vs. 54.3 %) had a documented psychiatric illness 
such as anxiety, depressive disorders or sleep disturbances at baseline. There was no 
increase in the co-prescription of anxiolytics /sedatives /anti-depressant over time 
comparing rimonabant treated patients with controls. CONCLUSIONS: The majority 
of patients were prescribed rimonabant according to the given rules for indication and 
reimbursement. Weight reduction in the total cohort and reduction of HbA1c in 
patients with type 2 diabetes during the follow up year, were of similar magnitude as 
reported in various clinical trials. The safety analysis did not signal any increase in 
adverse events including psychiatric illness in patients treated with rimonabant more 
than six months.
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OBJECTIVES: To review recommendations of Health Technology Assessment (HTA) 
reports on sibutramine and orlistat in the treatment of obesity from France (HAS), 
UK (NICE), Sweden (TLV), Belgium (KCE) and Canada (CADTH). METHODS: HTA 
reports were identiﬁed by searching each HTA agency’s homepages using “sibu-
tramine” OR “orlistat” as keywords. Results were categorised as Recommended, 
Restricted recommended and Not Recommended in comparison to the indication for 
marketing authorisation given by EMEA. RESULTS: A total of eleven HTA reports 
were identiﬁed; six assessing orlistat and ﬁve sibutramine. Four HTA-reports on orli-
stat gave a positive recommendation while the remaining HTA reports did not recom-
mend use/funding. Reasons for not recommending orlistat included; insufﬁcient data 
to quantify obesity-related morbidity and mortality, uncertainties in compliance due 
to side effects, treatment effect was not maintained after discontinuation, lack of long 
term safety data, and poor deﬁnition of indication “metabolic syndrome”. For sibu-
tramine, three reports concluded Recommended, one Restricted recommended and 
one Not recommended. Reasons for a negative and restricted recommendation 
included; insufﬁcient data to quantify obesity-related morbidity and mortality, and 
lack of long term safety data. CONCLUSIONS: Quantity of effect of weight loss on 
morbidity and mortality, deﬁning an appropriate indication for initiating pharmaco-
logical treatment and adequate provision of data on long-term safety and effectiveness 
appears to be main issues driving a negative recommendation. These issues must be 
addressed in the development of a clinical documentation of future pharmacological 
treatments of obesity. It is interesting to notice that similar evidences lead to very           
contradictory outcome reﬂecting broader way to scrutinize evidences for HTA decision 
making.
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OBJECTIVES: To clarify how the standard estimate of incremental cost-effectiveness 
ratio (ICER) theoretically changes, affected by the uncertainty accompanied with sta-
tistical errors and probability of truth in evidence-based practice, and further to 
investigate how the ‘risk’-adjusted ICER (r-ICER) could be used in the analysis of 
efﬁciency frontier by IQWiG. METHODS: A decision analysis was performed using: 
1) probability of truth, 1 – p, for a null hypothesis (or p for the alternative hypothesis), 
2) type I error (A), and 3) type II error (B).The decision tree modeled a patient facing 
the alternative decisions for treatment: evidence-based (Teb) or conventional (Tc), 
considering the choices: 1) Tc: if no evidence available about a new treatment A, then 
the patient takes a conventional treatment B, and 2) Teb: if positive evidence of a 
clinical trial available, then take the treatment A, whereas if the evidence is negative, 
take the treatment B. Given a pair of beneﬁt and cost for the treatments A and B, 
respectively noted as (Ea, Ca) and (Eb, Cb) at the terminal node, then the operations 
